Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1a/1b, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of the COVID-19 (SARS-CoV-2) Vaccine Candidates VBI-2902a and VBI-2905a in Healthy Adults

NCT04773665 is registered in ClinicalTrials.gov with VBI Vaccines Inc. as lead sponsor.

NCT NCT04773665
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04773665 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1a/1b, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of the COVID-19 (SARS-CoV-2) Vaccine Candidates VBI-2902a and VBI-2905a in Healthy Adults
Lead sponsor
VBI Vaccines Inc.
Phase
Phase 1
Overall status
Completed
Start date
March 15, 2021
Completion date
November 14, 2022
Enrollment
114 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

covid19